Here’s a round-up on Veru Inc!
Positive Results from Phase 3 trial of Sabizabulin Veru, Inc. (NASDAQ: VERU) announced the publication of results from a Phase 3 study evaluating the safety and efficacy of oral sabizabulin for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome...
